ERBB2 and gastric adenocarcinoma: Patients with HER2-positive gastric adenocarcinoma and esophagogastric junction adenocarcinoma were randomly assigned to either a group in which pembrolizumab was added to trastuzumab + chemotherapy or a placebo group.